Melobax (Meloxicam)

Meloxicam works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever. By lowering prostaglandin levels, meloxicam alleviates these symptoms while sparing COX‑1 activity that protects the stomach lining.

The specific dose of Melobax is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and other individual factors. Only a qualified healthcare professional should set the appropriate dosing regimen.

Safety data for meloxicam in pregnancy and lactation are limited. It is generally advised to avoid NSAIDs, including meloxicam, during the third trimester of pregnancy and to discuss potential risks with a healthcare provider if use is considered while pregnant or breastfeeding.

To request Melobax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melobax (meloxicam) offers preferential COX‑2 inhibition, which may provide similar analgesic and anti‑inflammatory benefits as non‑selective NSAIDs while potentially reducing gastrointestinal side effects. However, individual response varies, and clinicians weigh efficacy, safety profile, and patient comorbidities when selecting an NSAID.

Melobax should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources to maintain stability and potency throughout its shelf life.

Melobax is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may help reduce mild gastrointestinal discomfort that some patients experience.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver enzyme elevation, renal impairment, and rare anaphylactic reactions. Patients should be monitored closely for any warning signs.

Melobax should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe heart failure, uncontrolled hypertension, and patients with significant renal or hepatic impairment unless specifically directed by a physician.